CRISPR-Cas systems for genome editing of mammalian cells

Indra Mani, Takayuki Arazoe, Vijai Singh

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

3 Citations (Scopus)

Abstract

In the past decade, ZFNs and TALENs have been used for targeted genome engineering and have gained scientific attention. It has demonstrated huge potential for gene knockout, knock-in, and indels in desired locations of genomes to understand molecular mechanism of diseases and also discover therapy. However, both the genome engineering techniques are still suffering from design, screening and validation in cell and higher organisms. CRISPR-Cas9 is a rapid, simple, specific, and versatile technology and it has been applied in many organisms including mammalian cells. CRISPR-Cas9 has been used for animal models to modify animal cells for understanding human disease for novel drug discovery and therapy. Additionally, base editing has also been discussed herewith for conversion of C/G-to-T/A or A/T-to-G/C without DNA cleavage or donor DNA templates for correcting mutations or altering gene functions. In this chapter, we highlight CRISPR-Cas9 and base editing for desired genome editing in mammalian cells for a better understanding of molecular mechanisms, and biotechnological and therapeutic applications.

Original languageEnglish
Title of host publicationReprogramming the Genome
Subtitle of host publicationCRISPR-Cas-based Human Disease Therapy
EditorsVijai Singh
PublisherElsevier B.V.
Pages15-30
Number of pages16
ISBN (Print)9780323853231
DOIs
Publication statusPublished - Jan 2021

Publication series

NameProgress in Molecular Biology and Translational Science
Volume181
ISSN (Print)1877-1173
ISSN (Electronic)1878-0814

Keywords

  • Animal models
  • CRISPR-Cas9 system
  • TALENs
  • Therapeutic
  • ZFNs
  • sgRNA

Fingerprint

Dive into the research topics of 'CRISPR-Cas systems for genome editing of mammalian cells'. Together they form a unique fingerprint.

Cite this